Cargando…

Cost-Effectiveness of Second-Line Chemotherapy/Biologics among Elderly Metastatic Colon Cancer Patients

INTRODUCTION: Advancements in chemotherapy treatment have improved the clinical management of metastatic colon cancer (mCC) patients. An increasing number of elderly mCC patients receive various combinations of regimens in second-line chemotherapy/biologics treatment (Tx2) after first-line treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Zhiyuan, Onukwugha, Eberechukwu, Hanna, Nader, Bikov, Kaloyan, Seal, Brian, Mullins, C. Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4115177/ https://www.ncbi.nlm.nih.gov/pubmed/25022528 http://dx.doi.org/10.1007/s12325-014-0134-8

Ejemplares similares

Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients
por: Zheng, Zhiyuan, et al.
Publicado: (2014)

Clinical and demographic characteristics associated with the receipt of chemotherapy treatment among 7951 elderly metastatic colon cancer patients
por: Reese, Emily S, et al.
Publicado: (2013)

Sequential Therapies and the Cost-Effectiveness of Treating Metastatic Colon Cancer Patients
por: Woldemichael, Andinet, et al.
Publicado: (2016)

Concordance between administrative claims and registry data for identifying metastasis to the bone: an exploratory analysis in prostate cancer
por: Onukwugha, Eberechukwu, et al.
Publicado: (2014)

Prevalence and risk of skeletal complications and use of radiation therapy in elderly women diagnosed with metastatic breast cancer
por: Hussain, Arif, et al.
Publicado: (2018)

Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis
por: Hussain, Arif, et al.
Publicado: (2016)

Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis
por: Mattingly, T. Joseph, et al.
Publicado: (2019)

Burden of Co-Infection: A Cost Analysis of Human Immunodeficiency Virus in a Commercially Insured Hepatitis C Virus Population
por: Mattingly, T. Joseph, et al.
Publicado: (2019)

Big Data and Its Role in Health Economics and Outcomes Research: A Collection of Perspectives on Data Sources, Measurement, and Analysis
por: Onukwugha, Eberechukwu
Publicado: (2016)

Valuing diversity in value assessment: introducing the PhRMA Foundation Health Disparities Challenge Award
por: Onukwugha, Eberechukwu
Publicado: (2021)

Epidemiological Determinants of Advanced Prostate Cancer in Elderly Men in the United States
por: Jayasekera, Jinani, et al.
Publicado: (2019)

Why the Gap in Evaluating the Social Constructs and the Value of Medicines?
por: McRae, Jacquelyn, et al.
Publicado: (2021)

Skeletal-related events and mortality among men diagnosed with advanced prostate cancer: The impact of alternative measures of radiation to the bone
por: Onukwugha, Eberechukwu, et al.
Publicado: (2017)

Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis
por: Naiki, Taku, et al.
Publicado: (2018)

The Economic Burden of Comorbid Obstructive Sleep Apnea Among Patients with Chronic Obstructive Pulmonary Disease
por: Hong, Yoon Duk, et al.
Publicado: (2020)

Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front‐line regimens using the SEER‐Medicare data
por: Goto, Daisuke, et al.
Publicado: (2019)

A qualitative study to identify reasons for discharges against medical advice in the cardiovascular setting
por: Onukwugha, Eberechukwu, et al.
Publicado: (2012)

Cardiovascular event-free survival after adjuvant radiation therapy in breast cancer patients stratified by cardiovascular risk
por: Onwudiwe, Nneka C, et al.
Publicado: (2014)

Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
por: Cai, Hongfu, et al.
Publicado: (2021)

Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods
por: Aly, Abdalla, et al.
Publicado: (2015)

Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure
por: Kobayashi, Noritoshi, et al.
Publicado: (2017)

A Sustainable Strategy to Prevent Misuse of Antibiotics for Acute Respiratory Infections
por: Rattinger, Gail B., et al.
Publicado: (2012)

Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy: a network meta-analysis
por: Citterio, Chiara, et al.
Publicado: (2018)

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
por: Yamamoto, Shun, et al.
Publicado: (2021)

Changes in Opioid Utilization Following Tumor Necrosis Factor Inhibitor Initiation in Patients with Rheumatoid Arthritis
por: Park, Siyeon, et al.
Publicado: (2019)

Economic burden of interstitial lung disease in a commercially insured population with Sjögren syndrome in the United States
por: Lee, Tsung-Ying, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
por: Lin, Ying-Tao, et al.
Publicado: (2021)

FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study
por: Zaanan, Aziz, et al.
Publicado: (2014)

Evaluation of vinorelbine-based chemotherapy as the second or further-line treatment in patients with metastatic breast cancer
por: Cybulska-Stopa, Bożena, et al.
Publicado: (2013)

The prognostic value of D-dimer levels in metastatic osteosarcoma patients treated with second-line chemotherapy
por: Huang, Yujing, et al.
Publicado: (2016)

Exceptional Response to Second-Line Gemcitabine/Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma
por: Bukhari, Nedal, et al.
Publicado: (2021)

First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapy vs combination chemotherapy
por: Han, Sung Yong, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting
por: Lauren, Brianna, et al.
Publicado: (2020)

An ecological approach to monitor geographic disparities in cancer outcomes
por: Jayasekera, Jinani, et al.
Publicado: (2019)

Regional Chemotherapy Is a Valuable Second-Line Approach in Metastatic Esophageal Cancer after Failure to First-Line Palliative Treatment
por: Vashist, Yogesh, et al.
Publicado: (2022)

Cost‐effectiveness of second‐line ipilimumab for metastatic melanoma: A real‐world population‐based cohort study of resource utilization
por: Lu, Brandon, et al.
Publicado: (2023)

Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer
por: Pei, Zhengda, et al.
Publicado: (2023)

Multicenter phase II study of apatinib treatment for metastatic gastric cancer after failure of second-line chemotherapy
por: Ruan, Hanguang, et al.
Publicado: (2017)

Complete Radiologic Response of Metastatic Pancreatic Ductal Adenocarcinoma to Microwave Ablation Combined with Second-Line Palliative Chemotherapy
por: Blomstrand, Hakon, et al.
Publicado: (2020)

A phase II trial of cabazitaxel as second line chemotherapy in relapsed locally advanced and/or metastatic carcinoma of the penis
por: Challapalli, Amarnath, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_619oeqfdqoesfdmdnrai8v1eat